ArticleCureus2026
Transcatheter Aortic Valve Replacement for Severe Aortic Regurgitation in a Young Adult With Takayasu Arteritis: A Case Report.
Article in Cureus, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Takayasu arteritis (TAK) is a rare large-vessel vasculitis that can cause severe aortic regurgitation (AR) and heart failure in young adults. While surgical aortic valve replacement remains the standard treatment, transcatheter aortic valve replacement (TAVR) has emerged as a viable alternative in high-risk patients. We present the case of a 23-year-old woman with juvenile idiopathic arthritis (JIA) and TAK who developed refractory heart failure secondary to severe AR. Initial echocardiography revealed a left ventricular ejection fraction (LVEF) of 40%. Given active vasculitis, prohibitive surgical risk, and acute decompensation despite medical therapy, emergent TAVR was performed. The patient demonstrated remarkable clinical improvement with LVEF normalization to 56% at one-year follow-up. This case illustrates that TAVR can be successfully performed for severe AR in young adults with TAK when surgical risk is prohibitive, emphasizing the importance of aggressive perioperative inflammation control, multidisciplinary care, and individualized treatment strategies in vasculitis-associated valvular disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.